These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 35358872)

  • 41. Curcumin β-D-glucuronide exhibits anti-tumor effects on oxaliplatin-resistant colon cancer with less toxicity in vivo.
    Ozawa-Umeta H; Kishimoto A; Imaizumi A; Hashimoto T; Asakura T; Kakeya H; Kanai M
    Cancer Sci; 2020 May; 111(5):1785-1793. PubMed ID: 32163218
    [TBL] [Abstract][Full Text] [Related]  

  • 42. WTAP weakens oxaliplatin chemosensitivity of colorectal cancer by preventing PANoptosis.
    Tan YT; Li T; Wang RB; Liu ZK; Ma MY; Huang RZ; Mo HY; Luo SY; Lin JF; Xu RH; Ju HQ
    Cancer Lett; 2024 Nov; 604():217254. PubMed ID: 39270768
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Luteolin Shifts Oxaliplatin-Induced Cell Cycle Arrest at G₀/G₁ to Apoptosis in HCT116 Human Colorectal Carcinoma Cells.
    Jang CH; Moon N; Oh J; Kim JS
    Nutrients; 2019 Apr; 11(4):. PubMed ID: 30987009
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Zuo Jin Wan Reverses the Resistance of Colorectal Cancer to Oxaliplatin by Regulating the MALAT1/miR-200s/JNK Signaling Pathway.
    Wei Z; Zhou J; Yu H; Pu Y; Cheng Y; Zhang Y; Ji Q; Zhu H
    Evid Based Complement Alternat Med; 2022; 2022():3032407. PubMed ID: 36248422
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Suppressing the KIF20A/NUAK1/Nrf2/GPX4 signaling pathway induces ferroptosis and enhances the sensitivity of colorectal cancer to oxaliplatin.
    Yang C; Zhang Y; Lin S; Liu Y; Li W
    Aging (Albany NY); 2021 Mar; 13(10):13515-13534. PubMed ID: 33819186
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Nrf2 inhibition reverses the resistance of cisplatin-resistant head and neck cancer cells to artesunate-induced ferroptosis.
    Roh JL; Kim EH; Jang H; Shin D
    Redox Biol; 2017 Apr; 11():254-262. PubMed ID: 28012440
    [TBL] [Abstract][Full Text] [Related]  

  • 47. SIRT1 enhances oxaliplatin resistance in colorectal cancer through microRNA-20b-3p/DEPDC1 axis.
    Zhao B; Wang Y; Zhao X; Ni J; Zhu X; Fu Y; Yang F
    Cell Biol Int; 2022 Dec; 46(12):2107-2117. PubMed ID: 36200529
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Gfi-1 modulates HMGB1-Mediated autophagy to overcome oxaliplatin resistance in colorectal cancer.
    Liu W; Zhang Z; Zhang L; Jiang X; Chen C; Wu X; Zhao Q
    Heliyon; 2024 May; 10(9):e29859. PubMed ID: 38694127
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Methylation of the KEAP1 gene promoter region in human colorectal cancer.
    Hanada N; Takahata T; Zhou Q; Ye X; Sun R; Itoh J; Ishiguro A; Kijima H; Mimura J; Itoh K; Fukuda S; Saijo Y
    BMC Cancer; 2012 Feb; 12():66. PubMed ID: 22325485
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Chemoresistant colorectal cancer cells and cancer stem cells mediate growth and survival of bystander cells.
    Bose D; Zimmerman LJ; Pierobon M; Petricoin E; Tozzi F; Parikh A; Fan F; Dallas N; Xia L; Gaur P; Samuel S; Liebler DC; Ellis LM
    Br J Cancer; 2011 Nov; 105(11):1759-67. PubMed ID: 22045189
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Ailanthone increases oxidative stress in CDDP-resistant ovarian and bladder cancer cells by inhibiting of Nrf2 and YAP expression through a post-translational mechanism.
    Cucci MA; Grattarola M; Dianzani C; Damia G; Ricci F; Roetto A; Trotta F; Barrera G; Pizzimenti S
    Free Radic Biol Med; 2020 Apr; 150():125-135. PubMed ID: 32101771
    [TBL] [Abstract][Full Text] [Related]  

  • 52. DUB3 deubiquitinates and stabilizes NRF2 in chemotherapy resistance of colorectal cancer.
    Zhang Q; Zhang ZY; Du H; Li SZ; Tu R; Jia YF; Zheng Z; Song XM; Du RL; Zhang XD
    Cell Death Differ; 2019 Nov; 26(11):2300-2313. PubMed ID: 30778200
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The c-Myc/miR-27b-3p/ATG10 regulatory axis regulates chemoresistance in colorectal cancer.
    Sun W; Li J; Zhou L; Han J; Liu R; Zhang H; Ning T; Gao Z; Liu B; Chen X; Ba Y
    Theranostics; 2020; 10(5):1981-1996. PubMed ID: 32104496
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Vorinostat synergizes with EGFR inhibitors in NSCLC cells by increasing ROS via up-regulation of the major mitochondrial porin VDAC1 and modulation of the c-Myc-NRF2-KEAP1 pathway.
    Leone A; Roca MS; Ciardiello C; Terranova-Barberio M; Vitagliano C; Ciliberto G; Mancini R; Di Gennaro E; Bruzzese F; Budillon A
    Free Radic Biol Med; 2015 Dec; 89():287-99. PubMed ID: 26409771
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Poly(C)-binding protein 1 mediates drug resistance in colorectal cancer.
    Guo J; Zhu C; Yang K; Li J; Du N; Zong M; Zhou J; He J
    Oncotarget; 2017 Feb; 8(8):13312-13319. PubMed ID: 28076324
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Anti-tumor effects of CIK combined with oxaliplatin in human oxaliplatin-resistant gastric cancer cells in vivo and in vitro.
    Zhao Q; Zhang H; Li Y; Liu J; Hu X; Fan L
    J Exp Clin Cancer Res; 2010 Aug; 29(1):118. PubMed ID: 20799994
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Translationally controlled tumour protein TCTP is induced early in human colorectal tumours and contributes to the resistance of HCT116 colon cancer cells to 5-FU and oxaliplatin.
    Bommer UA; Vine KL; Puri P; Engel M; Belfiore L; Fildes K; Batterham M; Lochhead A; Aghmesheh M
    Cell Commun Signal; 2017 Feb; 15(1):9. PubMed ID: 28143584
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Different effects of epigenetic modifiers on the cytotoxicity induced by 5-fluorouracil, irinotecan or oxaliplatin in colon cancer cells.
    Ikehata M; Ogawa M; Yamada Y; Tanaka S; Ueda K; Iwakawa S
    Biol Pharm Bull; 2014; 37(1):67-73. PubMed ID: 24172061
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Inhibition of the NRF2/KEAP1 Axis: A Promising Therapeutic Strategy to Alter Redox Balance of Cancer Cells.
    Panieri E; Saso L
    Antioxid Redox Signal; 2021 Jun; 34(18):1428-1483. PubMed ID: 33403898
    [No Abstract]   [Full Text] [Related]  

  • 60. Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer.
    Fioravanti A; Canu B; Alì G; Orlandi P; Allegrini G; Di Desidero T; Emmenegger U; Fontanini G; Danesi R; Del Tacca M; Falcone A; Bocci G
    Eur J Pharmacol; 2009 Oct; 619(1-3):8-14. PubMed ID: 19695243
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.